Lawrence A Kenyon's Net Worth

$553 Thousand

Estimate Recalculated Sep 9, 2024 12:29AM EST

Who is Lawrence A Kenyon

Lawrence A Kenyon does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ALFACELL CORP, Outlook Therapeutics, Inc., PAR PHARMACEUTICAL COMPANIES, INC., Arno Therapeutics, Inc, and NEOPHARM INC.

SEC CIK

Lawrence A Kenyon's CIK is 0001230484

Past Insider Trading and Trends

2007 was Lawrence A Kenyon's most active year for acquiring shares with 7 total transactions. Lawrence A Kenyon's most active month to acquire stocks was the month of March. 2010 was Lawrence A Kenyon's most active year for disposing of shares, totalling 21 transactions. Lawrence A Kenyon's most active month to dispose stocks was the month of February. 2004 saw Lawrence A Kenyon paying a total of $398,200.00 for 20,000 shares, this is the most they've acquired in one year. In 2010 Lawrence A Kenyon cashed out on 50,087 shares for a total of $733,362.11, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

ALFACELL CORP

President, CEO and CFO
Updated Jul 25, 2012
Form 4
400.00K
Jul 25, 2012
400.00K
Grant
Jul 23
Form 3
Dec 23, 2011
25.00K
Form 4
25.00K
$2.14
$53.38K
Apr 12, 2007
25.00K
Purchase
Apr 11
Form 4
375.00K
Jan 18, 2007
375.00K
Grant
Jan 16
Form 3
Jan 18, 2007
Showing 5 results

Outlook Therapeutics, Inc.

CHIEF FINANCIAL OFFICER
Updated Mar 22, 2024
Form 4
12.50K
Mar 22, 2024
12.50K
Grant
Mar 20
Form 4
112.03%
10.00K
$1.83
$18.30K
Apr 20, 2021
18.93K
Purchase
Apr 20
Form 4
3.67M
Oct 05, 2020
3.67M
Grant
Oct 01
Form 4
450.00K
Jul 21, 2020
450.00K
Grant
Jul 17
Form 4
216.44K
Mar 20, 2020
216.44K
Grant
Mar 19
Form 4/A
-13.14%
-1.35K
$1.70
-$2.29K
Oct 15, 2019
8.93K
Sale
Sep 18
Form 4
-1.64%
-1.35K
$1.70
-$2.29K
Sep 23, 2019
80.86K
Sale
Sep 18
Form 4
450.00K
Sep 13, 2019
450.00K
Grant
Sep 12
Form 4
800.00K
Feb 19, 2019
800.00K
Grant
Feb 19
Form 4
43.70%
25.00K
$0.90
$22.38K
Feb 08, 2019
82.21K
Purchase
Feb 07
Form 4
-15.00%
-10.10K
$0.87
-$8.81K
Sep 18, 2018
57.21K
Sale
Sep 18
Form 4
500.00K
Aug 03, 2018
500.00K
Grant
Aug 01
Form 4
-27.99%
-26.16K
$1.13
-$29.57K
Dec 26, 2017
67.31K
Sale
Dec 22
Form 4
115.00%
50.00K
Dec 22, 2016
93.48K
Grant
Dec 21
Form 3/A
Dec 22, 2016
43.48K
Form 3
May 12, 2016
42.48K
Showing 16 results

PAR PHARMACEUTICAL COMPANIES, INC.

EVP, Chief Financial Officer
Updated Aug 04, 2010
Form 4
-30.57%
-6.31K
$26.90
-$169.79K
Aug 04, 2010
14.34K
Tax
Aug 02
Form 4
-20.15%
-21.44K
$19.13
-$260.36K
Mar 03, 2010
84.97K
Sale
Mar 03
Form 4
-4.16%
-897.00
$25.88
-$23.21K
Jan 12, 2010
20.65K
Tax
Jan 08
Form 4/A
21.65K
Jan 08, 2010
21.65K
Grant
Jan 04
Form 4
305.54%
32.48K
Jan 06, 2010
43.11K
Grant
Jan 04
Form 4
96.48K
Jan 12, 2009
96.48K
Grant
Jan 08
Form 3
Dec 18, 2008
Showing 7 results

Arno Therapeutics, Inc

Chief Financial Officer
Updated Feb 26, 2014
Form 4
223.44K
Feb 26, 2014
223.45K
Grant
Feb 24
Form 3
Feb 26, 2014
Showing 2 results

NEOPHARM INC

CFO and Secretary
Updated Jan 27, 2006
Form 4
25.00K
Jan 27, 2006
25.00K
Grant
Jan 25
Form 4
43.10K
$7.95
$342.65K
May 02, 2005
43.10K
Grant
Apr 28
Form 4
20.00K
$19.91
$398.20K
Feb 18, 2004
20.00K
Grant
Feb 17
Showing 3 results